Evidence map›Paper›PMID 37850241›Full record

ReviewJournal of neurochemistry2024

COVID-19 and the impact on Alzheimer's disease pathology.

Susana Furman, Kim Green, Thomas E Lane

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of neurochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Susana FurmanDepartment of Neurobiology & Behavior, School of Biological Sciences, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-0809-8992
Kim GreenDepartment of Neurobiology & Behavior, School of Biological Sciences, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-6049-6744
Thomas E LaneDepartment of Neurobiology & Behavior, School of Biological Sciences, University of California Irvine, Irvine, California, USA.ORCID 0000-0003-0392-0825
University of California, Irvine · US

Funding

Training in the Neurobiology of Aging and Alzheimers DiseaseT32AG000096 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI VIVEK SWARUP, Craig E Stark · 1985 to 2026
$9.6M
Defining mechanisms of disease and repair in a viral model of multiple sclerosisR35NS116835 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Thomas E Lane · 2020 to 2026
$5.0M
Alzheimer's Association 1051950NIA NIH HHS T32 AG000096NIH-NIA T32 AG00096NINDS NIH HHS R35 NS116835
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) has rapidly escalated into a global pandemic that primarily affects older and immunocompromised individuals due to underlying clinical conditions and suppressed immune responses. Furthermore, COVID-19 patients exhibit a spectrum of neurological symptoms, indicating that COVID-19 can affect the brain in a variety of manners. Many studies, past and recent, suggest a connection between viral infections and an increased risk of neurodegeneration, raising concerns about the neurological effects of COVID-19 and the possibility that it may contribute to Alzheimer's disease (AD) onset or worsen already existing AD pathology through inflammatory processes given that both COVID-19 and AD share pathological features and risk factors. This leads us to question whether COVID-19 is a risk factor for AD and how these two conditions might influence each other. Considering the extensive reach of the COVID-19 pandemic and the devastating impact of the ongoing AD pandemic, their combined effects could have significant public health consequences worldwide.

Indexed as

Alzheimer DiseaseCOVID-19BrainHumansPandemicsRisk FactorsSARS-CoV-2Alzheimer's diseasecoronaviruscoronavirus disease 2019neuropathology

Identifiers

PMID37850241
PMCPMC11024062
OpenAlexW4387729656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.